Biphasic or Mixed
The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas
Human Pathology 2020 September 2 [Link] Sarita Prabhakaran, Ashleigh Hocking, Chankyung Kim, Matthew Hussey, Sonja Klebe Abstract Malignant pleural mesothelioma is associated with asbestos exposure and poor outcomes. The usefulness of immunohistochemistry for diagnosis of sarcomatoid mesothelioma, especially the desmoplastic type, is limited, and more effective markers are required. GATA binding protein 3 (GATA3) has…
Read MoreTrabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
Clinical Lung Cancer 2020 July 3 [Link] Diego Cortinovis, Federica Grosso, Luciano Carlucci, Paolo Andrea Zucali, Giulia Pasello, Marcello Tiseo, Francesca Sperandi, Lital Hollander, Francesca Galli, Valter Torri, Eliana Rulli, Stefania Canova, Antonio Maconi, Paolo Bidoli, Giovanni Luca Ceresoli , Maurizio D’Incalci, ATREUS investigators Abstract Introduction: New therapeutic approaches in unresectable malignant pleural mesothelioma (MPM)…
Read MoreDeterminants of plasma calretinin in patients with malignant pleural mesothelioma
BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…
Read MoreHeadspace analysis of mesothelioma cell lines differentiates biphasic and epithelioid sub-types
Journal of Breath Research 2020 July 30 [Link] Liam David Little, Vikki Amanda Carolan, K Elizabeth Allen, Laura Margaret Cole, Sarah Louise Haywood-Small Abstract Malignant mesothelioma (MM) is an incurable cancer. MM is often misdiagnosed, with a poor 5-year survival and limited treatment options. The discovery of endogenous volatile organic compounds (VOCs) is required in…
Read MorePossible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
Respiratory Research 2020 July 16 [Link] Masataka Kojima, Kazunori Kajino, Shuji Momose, Nadila Wali, May Thinzar Hlaing, Bo Han, Liang Yue, Masaaki Abe, Tomoaki Fujii, Katsuhisa Ikeda, Okio Hino Abstract Background: Mesothelioma is histologically divided into three subgroups: epithelioid, sarcomatoid, and biphasic types. The epithelioid or sarcomatoid type is morphologically defined by polygonal or spindle-like…
Read MoreTesting for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Cancer Cytopathology 2020 July 17 [Link] Martin Chevrier, Sara E Monaco, Jacob A Jerome, Francoise Galateau-Salle, Andrew Churg, Sanja Dacic Abstract Background: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16…
Read MoreAmrubicin in Previously Treated Patients With Malignant Pleural Mesothelioma: A Phase II Study
Thoracic Cancer 2020 May 28 [Link] Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae Abstract Background: The aim of this study was to assess the efficacy and safety of amrubicin for previously treated…
Read MoreLocalized Biphasic Malignant Mesothelioma Presenting as a Giant Pelvic Wall Mass: A Rare Case Report and Literature Review
BMC Medical Imaging 2020 May 6 [Link] Yunsong Liu, Jingjun Wu, Ying Zhao, Pengxin Zhang, Zhengyu Hua, Wan Dong, Tao Lin, Ailian Liu Abstract Background: Localized biphasic MPeM is rare in clinical practice, we reviewed 8 cases of localized biphasic MPeM (including our present case), and summarized the clinical and imaging features of the disease.…
Read MoreSurgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
Frontiers in Oncology 2020 March 24 [Link] Breen WG, Garces YI, Olivier KR, Park SS, Merrell KW, Nichols FC, Peikert TD, Molina JR, Mansfield AS, Roden AC, Blackmon SH, Wigle DA Abstract Background: The optimal treatment sequence for localized malignant pleural mesothelioma (MPM) is controversial. We aimed to assess outcomes and toxicities of treating localized…
Read MoreSurgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
Translational Lung Cancer Research 2020 February [Link] Woodard GA, Jablons DM Abstract Extrapleural pneumonectomy (EPP) and pleurectomy decortication (PD) are radical operations for malignant pleural mesothelioma (MPM) that remain controversial among thoracic surgeons. There is a lack of randomized evidence to support a survival benefit when major surgical resection is included in multi-modality treatment regimens.…
Read More